AR112062A1 - Formas cristalinas de seletalisib - Google Patents
Formas cristalinas de seletalisibInfo
- Publication number
- AR112062A1 AR112062A1 ARP180101467A ARP180101467A AR112062A1 AR 112062 A1 AR112062 A1 AR 112062A1 AR P180101467 A ARP180101467 A AR P180101467A AR P180101467 A ARP180101467 A AR P180101467A AR 112062 A1 AR112062 A1 AR 112062A1
- Authority
- AR
- Argentina
- Prior art keywords
- seletalisib
- crystal forms
- oncological
- nociceptive
- neurodegenerative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Inhibidores selectivos de enzimas quinasa PI3, en particular de la isoforma PI3Kd humana, en consecuencia, son beneficiosas en la medicina, por ejemplo, en el tratamiento de afecciones inflamatorias, autoinmunes, cardiovasculares, neurodegenerativas, metabólicas, oncológicas, nociceptivas u oftálmicas. Reivindicación 1: Forma B de seletalisib, representada por la fórmula (1) caracterizada porque n es por lo menos aproximadamente 0,1 y no más de aproximadamente 2,1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1708856.8A GB201708856D0 (en) | 2017-06-02 | 2017-06-02 | Seletalisib crystalline forms |
Publications (1)
Publication Number | Publication Date |
---|---|
AR112062A1 true AR112062A1 (es) | 2019-09-18 |
Family
ID=59349914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180101467A AR112062A1 (es) | 2017-06-02 | 2018-06-01 | Formas cristalinas de seletalisib |
Country Status (17)
Country | Link |
---|---|
US (1) | US11059820B2 (es) |
EP (1) | EP3630760A1 (es) |
JP (1) | JP7264829B2 (es) |
KR (1) | KR102591329B1 (es) |
CN (2) | CN110709399A (es) |
AR (1) | AR112062A1 (es) |
AU (1) | AU2018276243B2 (es) |
BR (1) | BR112019023592A8 (es) |
CA (1) | CA3062533A1 (es) |
CL (1) | CL2019003510A1 (es) |
CO (1) | CO2019014026A2 (es) |
EA (1) | EA201992839A1 (es) |
GB (1) | GB201708856D0 (es) |
IL (1) | IL270937A (es) |
MX (1) | MX2019013518A (es) |
RU (1) | RU2019143761A (es) |
WO (1) | WO2018219772A1 (es) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5620981A (en) * | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
US20040106794A1 (en) * | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
GB0428475D0 (en) * | 2004-12-30 | 2005-02-02 | 4 Aza Bioscience Nv | Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
AR082799A1 (es) * | 2010-09-08 | 2013-01-09 | Ucb Pharma Sa | Derivados de quinolina y quinoxalina como inhibidores de quinasa |
KR20170010369A (ko) * | 2014-05-27 | 2017-01-31 | 알미랄, 에스.에이. | 병용물 |
GB201506786D0 (en) | 2015-04-21 | 2015-06-03 | Ucb Biopharma Sprl | Therapeutic use |
GB201608797D0 (en) | 2016-05-19 | 2016-07-06 | Ucb Biopharma Sprl | Therapeutic use |
-
2017
- 2017-06-02 GB GBGB1708856.8A patent/GB201708856D0/en not_active Ceased
-
2018
- 2018-05-24 WO PCT/EP2018/063640 patent/WO2018219772A1/en active Application Filing
- 2018-05-24 EA EA201992839A patent/EA201992839A1/ru unknown
- 2018-05-24 MX MX2019013518A patent/MX2019013518A/es unknown
- 2018-05-24 RU RU2019143761A patent/RU2019143761A/ru unknown
- 2018-05-24 CA CA3062533A patent/CA3062533A1/en active Pending
- 2018-05-24 KR KR1020197037460A patent/KR102591329B1/ko active IP Right Grant
- 2018-05-24 CN CN201880036440.9A patent/CN110709399A/zh active Pending
- 2018-05-24 CN CN202210296993.6A patent/CN114573580A/zh active Pending
- 2018-05-24 JP JP2019566167A patent/JP7264829B2/ja active Active
- 2018-05-24 AU AU2018276243A patent/AU2018276243B2/en active Active
- 2018-05-24 EP EP18728337.9A patent/EP3630760A1/en active Pending
- 2018-05-24 US US16/615,992 patent/US11059820B2/en active Active
- 2018-05-24 BR BR112019023592A patent/BR112019023592A8/pt unknown
- 2018-06-01 AR ARP180101467A patent/AR112062A1/es unknown
-
2019
- 2019-11-26 IL IL270937A patent/IL270937A/en unknown
- 2019-11-29 CL CL2019003510A patent/CL2019003510A1/es unknown
- 2019-12-12 CO CONC2019/0014026A patent/CO2019014026A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
US11059820B2 (en) | 2021-07-13 |
KR102591329B1 (ko) | 2023-10-18 |
CA3062533A1 (en) | 2018-12-06 |
IL270937A (en) | 2020-01-30 |
CN110709399A (zh) | 2020-01-17 |
CN114573580A (zh) | 2022-06-03 |
BR112019023592A8 (pt) | 2023-05-09 |
KR20200012902A (ko) | 2020-02-05 |
MX2019013518A (es) | 2020-02-10 |
US20200095246A1 (en) | 2020-03-26 |
WO2018219772A1 (en) | 2018-12-06 |
AU2018276243B2 (en) | 2021-11-25 |
EA201992839A1 (ru) | 2020-04-08 |
JP7264829B2 (ja) | 2023-04-25 |
CL2019003510A1 (es) | 2020-04-17 |
CO2019014026A2 (es) | 2020-01-17 |
JP2020521793A (ja) | 2020-07-27 |
EP3630760A1 (en) | 2020-04-08 |
AU2018276243A1 (en) | 2019-12-19 |
BR112019023592A2 (pt) | 2020-05-26 |
RU2019143761A (ru) | 2021-07-09 |
GB201708856D0 (en) | 2017-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500086A1 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
JOP20190283B1 (ar) | طريقة لتصنيع أجسام مضادة ثنائية النوعية، والأجسام المضادة ثنائية النوعية والاستخدام العلاجي لها | |
WO2019118785A3 (en) | Inhibitors of integrated stress response pathway | |
MX2018006223A (es) | Moduladores de ror-gamma. | |
UY37098A (es) | Moduladores de ror-gamma | |
EA201792688A1 (ru) | Производные бензоксазинона и его аналоги в качестве модуляторов активности tnf | |
MX2019015311A (es) | Composiciones de ésteres de ácido cannabidiólico y usos de las mismas. | |
MX2019011784A (es) | Compuestos de aril ciclopropil-amino-isoquinolinil amida. | |
BR112019003232A2 (pt) | compostos de beta-amino-isoquinolinil amida, composições que o incluem e métodos de obtenção | |
WO2016081826A3 (en) | Envenomation therapies and related pharmaceutical compositions, systems and kits | |
MY197758A (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
MY192532A (en) | Liquid pharmaceutical composition | |
PH12021500012A1 (en) | Inhibitors of keapi-nrf2 protein-protein interaction | |
EA201890747A1 (ru) | Способы лечения воспалительных заболеваний | |
CL2020003083A1 (es) | Inhibidores de masp-2 y métodos de uso | |
MX2020013269A (es) | Inhibidores de la vía de respuesta al estrés integrada. | |
CO2017012988A2 (es) | Agentes, usos y métodos para el tratamiento | |
WO2016030334A3 (en) | Methods, agents and compositions for treatment of inflammatory conditions | |
WO2016170124A3 (en) | Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior | |
PH12016501434A1 (en) | Compositions for use in the treatment of allergic conditions | |
EA201791937A1 (ru) | Противовоспалительные полипептиды | |
AR112062A1 (es) | Formas cristalinas de seletalisib | |
CL2019002840A1 (es) | Formas cristalinas de (s)-afoxolaner. | |
MX2019013785A (es) | Metodos y tratamiento de trauma. | |
WO2017042577A8 (en) | Novel therapy |